AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01042522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01042522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide Phosphate
Description: Given IV
Study NCT01042522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02400411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: margarine
Study NCT03185546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate nicotine level e-liquid
Description: Participants are provided with moderate nicotine level e-liquid for 13 weeks
Study NCT03185546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low nicotine level e-liquid
Description: Participants are provided with very low or nicotine-free nicotine level e-liquid for 13 weeks
Study NCT03185546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Flavors
Description: Participants can choose e-liquid flavors from a selection of tobacco flavors
Study NCT03185546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco and non-tobacco e-liquid flavors
Description: Participants can choose e-liquid flavors from a selection of flavors that includes tobacco and non-tobacco choices
Study NCT04216173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture weekly for 12 consecutive weeks. Acupuncture protocol consists of both scalp and body acupuncture points.
Study NCT01130922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin per IV
Description: intravenous administration of 400 mg moxifloxacin (as a 1h-infusion)
Study NCT01130922 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin per os
Description: oral administration of 400 mg moxifloxacin in a single dose
Study NCT01023789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABSORB BVS
Description: Absorb Bioresorbable Vascular Scaffold (BVS) System implantation
Study NCT01368796 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agriflu
Description: 0.5mL dose IM vaccination
Study NCT01368796 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad
Description: 0.5mL dose of vaccine given IM
Study NCT01368796 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intanza
Description: 0.5mL dose vaccine given IM
Study NCT01368796 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip
Description: 0.5mL dose vaccine given IM
Study NCT05547945 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Promotion Program
Description: The health promotion program included knowledge guidance on ADHD disease, physical activity, diet nutrition, parental training/stress adjustment, related social welfare resources, mindfulness relaxation, and yoga.
Study NCT05547945 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: The control group received as usual care.
Study NCT03594552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose placebo (oral tablet)
Study NCT01042522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT02977260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thin/Low Energy
Description: Thin textured rice meal (ground rice grains) with lower energy density (0.57 kcal/g)
Study NCT02977260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thin/High Energy
Description: Thin textured rice meal (ground rice grains) with higher energy density (1.01 kcal/g)
Study NCT02977260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thick/Low Energy
Description: Thicker textured rice meal (whole rice grains) with lower energy density (0.57 kcal/g)
Study NCT02977260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thick/High Energy
Description: Thicker textured rice meal (whole rice grains) and high energy density (1.01 kcal/g)
Study NCT01972165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini-incision carpal tunnel release
Study NCT01972165 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic carpal tunnel release
Study NCT04113265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUNEKOS ® Body
Description: SUNEKOS ® Body is a medical device (class III). The study product was injected at level of the inner thighs, knees and arms by needle (29 G) using the interstitial fluid technique (IFT)
Study NCT03128762 — intervention group
Intervention type: BIOLOGICAL
Intervention: ILC2 levels in blood
Description: The levels of circulating ILC2 cells relative to other lymphocytes will be determined via flow cytometry
Study NCT02253498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation (DBS)
Study NCT00485667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKY0402
Description: Subects received either 300mg or 450mg
Study NCT00485667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: Subects received either 300mg or 450mg
Study NCT00485667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Study NCT02400411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ham
Study NCT02400411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: soup
Study NCT02400411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rye bread
Study NCT02040727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Supervised strength training 3 days per week for 24 weeks
Study NCT02040727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No Resistance Training
Description: No supervised strength training throughout the study
Study NCT02097017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: will local application of lidocaine to the cervix alleviate pain of laminaria insertion
Study NCT02097017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Study NCT00002975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid
Study NCT01943357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self Management Program
Description: The interventions include modeling and action-planning to enhance self-efficacy.
Study NCT01699971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernia repair
Description: Hernia repair admodum Lichtenstein with polypropylene mesh
Study NCT00485667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin 400mg
Study NCT02533089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KT intervention
Description: Multifaceted KT intervention employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
Study NCT00872222 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pinnacle™ Acetabular System
Description: A cementless acetabular cup with ceramic liner for use in total hip replacement
Study NCT02335502 — intervention group
Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium neurostimulator
Study NCT00908284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Participants will exercise in the study exercise laboratory for 1 hour on 2 nonconsecutive days a week for 12 weeks. The program will consist of a warm-up with flexibility exercises, aerobic conditioning, a muscular circuit, and a cool-down period with flexibility training.
Study NCT00485667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg
Study NCT00485667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo injection
Study NCT00485667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Study NCT00485667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injection
Study NCT00485667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Study NCT00485667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Study NCT03552692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax (ABT-199) will be administered orally (800 mg daily). Patients will receive ABT-199 until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator determines that further therapy is not in the patient's best interest.~Tumor Lysis Syndrome (TLS) is an important identified risk for Venetoclax in oncology studies. Since there are no available data on the risk of TLS in PTCL, the risk of TLS development should be closely monitored during the study.~to avoid TLS ABT-199 will be administered according the following ramp up: W eek 1 day 1: 20 mg W 1 day 2-3: 50 mg W 1 day 4-7: 100 mg W 2: 200 mg W 3: 400 mg W 4 and following: 800 mg
Study NCT04377009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet (SHUTi)
Description: Cognitive behavioral therapy delivered via internet-guided program customized for military service members
Study NCT04377009 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education Control Program
Description: Online portal designed to inform participants about healthy lifestyle activities and general insomnia information
Study NCT02061891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive coronary evaluation (Deferred)
Description: Invasive coronary angiography and revascularization (PCI/CABG)
Study NCT02061891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Invasive coronary evaluation (Acute)
Description: Invasive coronary angiography and revascularization (PCI/CABG)
Study NCT01204294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin once daily
Study NCT01204294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin twice or three time per day
Study NCT04605094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab by subcutaneous injection until Week 16, and then benralizumab by subcutaneous injection during the extension period.
Study NCT04605094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo / Benralizumab
Description: Placebo by subcutaneous injection until Week 16, then benralizumab by subcutaneous injection until Week 52.
Study NCT01820208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: G-CSF
Description: G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
Study NCT01820208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
Study NCT03928691 — intervention group
Intervention type: DRUG
Intervention: Magnesium Sulfate
Description: 4 gram MgSo4 diluted in 150 cc saline infused IV within 30 minutes as loading dose then the patient will receive the maintenance dose of 1gram MgSo4 per hour for 6 hours.
Study NCT01667627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bio-25
Description: Each capsule of the multispecies probiotic combination Bio-25 consists of 25 billion live bacteria.~Each type of bio-25 contains billions of live lactic acid bacteria in defined ratios of lyophilized Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasein, Lactobacillus casei, Bifidobacterium bifidum,Lactobacillus lactis, Lactobacillus rhamnosus,and Streptococcus thermophilus.
Study NCT01667627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo
Study NCT03283345 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified radical mastectomy
Description: systemic responses to trauma are compared with evaluating inflammatory cytokine levels between premenopausal and postmenopausal patient groups with different estrogen levels who underwent modified radical mastectomy.
Study NCT01537640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR231893 (REGN668) DP1
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT01537640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR231893 (REGN668) DP2
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT01982318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VitroGro® ECM
Study NCT01982318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dulbecco's Phosphate Buffered Saline
Study NCT01549080 — intervention group
Intervention type: DRUG
Intervention: Yisuishengxue Granule
Description: Yisui Shengxue Granules，produced by pharmaceutical factory of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, is made from the herbs of Shan Zhu Yu (Fructus Corni), He Shou Wu (Radix Polygoni Multiflori), Shu Di Huang (Radix Rehmanniae Preparata), Huang Qi (Radix Astragali) and etc.Yisui Shengxue Granules：12g/bag， Registration Number：20110602； Yisui Shengxue Granules replacer (placebo)：12g/bag，Registration Number：20110519；Treatment group：Yisui Shengxue Granules，1 bag, tid, po； Control group: Yisui Shengxue Granules replacer (placebo), 1 bag, tid, po; Intervention for 12 weeks. Follow-up 3 months later after stopping the drug intervention.
Study NCT02146118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg/day q 4 weeks
Study NCT02146118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Silybin-phytosome
Description: Silybin-phytosome 1g bid/day q 4 weeks
Study NCT02097550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth Intervention
Description: Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
Study NCT03331445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation
Description: Inhaled Nitric Oxide 160ppm balance air
Study NCT03677063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No dressing
Description: Then, care is the same and exit-site remains covered with an occlusive dressing to promote tunnel epithelialization and healing. The shower is forbidden during this period.
Study NCT04193748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical pomegranate seeds and peel extracts
Description: Topical pomegranate seeds and peel extracts in the form of gel
Study NCT04193748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical pomegranate seeds and peel extracts
Description: Topical pomegranate seeds and peel extracts in the form of gel
Study NCT03880266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrronium cloth, 2.4%
Description: Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium
Study NCT01699971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernia repair
Description: Hernia repair with Ultra Pro Hernia System (UHS)
Study NCT01699971 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hernia repair
Description: Hernia repair with Prolene Hernia System(PHS)
Study NCT02188043 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relay Model
Description: The Clinical staff hand out and collect lifestyle - questionnaires to admitted patients, and screen by 10 alcohol questions (AUDIT) , and report score to outpatient Alcohol Clinic.~Based on the questionnaire that the patient filled out, the Alcohol therapist perform a brief Motivational Intervention on patients with an AUDIT score of 8+, focusing the patients alcohol consumption habits and offer an appointment to patients with an AUDIT score of 16+.
Study NCT02299973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMT with donor stool
Description: fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from a healthy pool of donors and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the treatment group
Study NCT02299973 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: FMT with own stool
Description: fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from the patients and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the control group
Study NCT00908284 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Participants will attend group sessions once a week for 12 weeks to watch videos, including some exercise videos, and play games that do not require physical activity.
Study NCT00591734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
Study NCT00591734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg by mouth daily
Study NCT03622281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality improvement intervention using artificial intelligence
Description: Colonoscopists received performance measure monitoring and feedback
Study NCT00830921 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.
Study NCT00943683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
Study NCT00943683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
Study NCT00468897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSG XR
Description: RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
Study NCT02893267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
Study NCT02893267 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Nerve Stimulation
Description: The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
Study NCT02893267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Participants will receive 8 60-minute sessions of outpatient therapy over a 4 week period concurrent with PNS or sham-PNS treatment. Therapy may include: Proper Positioning and Handling, Therapeutic positioning and Strengthening Exercises, Mirror Therapy, Task-specific Therapy, Home Exercise Program, and a Mental Practice program.
Study NCT02893267 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Participants will receive 8 60-minute sessions of outpatient therapy over a 4 week period concurrent with PNS or sham-PNS treatment. Therapy may include: Proper Positioning and Handling, Therapeutic positioning and Strengthening Exercises, Mirror Therapy, Task-specific Therapy, Home Exercise Program, and a Mental Practice program.